NCT01104155 2023-06-22
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
Eisai Inc.
Phase 2 Completed
Eisai Inc.
Eisai Inc.
Corcept Therapeutics
National Cancer Institute (NCI)
Eisai Inc.